Yahoo Finance

Diagonal Therapeutics Announces Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Disease-Modifying, Clustering Antibody Pipeline

WATERTOWN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe ...
Yahoo Finance

Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary ...

WATERTOWN, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying ...
MarketWatch

Diagonal Therapeutics Announces Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Disease-Modifying, Clustering Antibody Pipeline

The MarketWatch News Department was not involved in the creation of this content. Financing co-led by Sanofi Ventures and Janus Henderson Investors, with participation from new investors Deep Track ...